12/3
08:00 am
lfwd
Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval
High
Report
Lifeward Broadens Reimbursement Coverage for ReWalk 7 Personal Robotic Exoskeleton as Humana Medicare Advantage Plan Issues Prior Authorization Approval
11/18
08:03 am
lfwd
Lifeward (NASDAQ:LFWD) had its price target lowered by analysts at HC Wainwright from $13.00 to $4.50. They now have a "buy" rating on the stock.
Low
Report
Lifeward (NASDAQ:LFWD) had its price target lowered by analysts at HC Wainwright from $13.00 to $4.50. They now have a "buy" rating on the stock.
11/17
08:00 am
lfwd
UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton
Medium
Report
UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton
11/14
08:00 am
lfwd
Lifeward Ltd. Reports Third Quarter 2025 Financial Results
Medium
Report
Lifeward Ltd. Reports Third Quarter 2025 Financial Results
11/10
07:00 am
lfwd
Lifeward to Report Third Quarter Financial Results on November 14, 2025
Low
Report
Lifeward to Report Third Quarter Financial Results on November 14, 2025
9/9
08:30 am
lfwd
First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton
Low
Report
First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton
9/8
08:30 am
lfwd
Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton
Low
Report
Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton